Cosmetic cross-reference

103-50-4

CAS 103-50-4

103-50-4 (CAS 103-50-4) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
103-50-4
CAS Number
103-50-4
UNII
2O6CNO27RJ
InChIKey
MHDVGSVTJDSBDK-UHFFFAOYSA-N
ChEMBL ID
CHEMBL152299
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Dibenzyl Ether
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 38364.92 nM 5 -
SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Dibenzyl Ether 1747705 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 103-50-4 used for in pharmaceutical contexts?

103-50-4 (CAS 103-50-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 103-50-4?

No adverse-event association or SIDER side-effect rows are rendered for 103-50-4 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 103-50-4 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Dibenzyl Ether with EU status "permitted".

What clinical phase is 103-50-4 in?

No phase 1-4 clinical development badge is rendered for 103-50-4 because the matched compound identifier rows do not contain a max-phase value.